Objective-We aimed to determine the effect of mechanistic target of rapamycin inhibitor everolimus on abdominal aortic aneurysm within the angiotensin II (A2)-infused apolipoprotein E-deficient mouse model. Approach and Results-Abdominal aortic aneurysm was induced via subcutaneous infusion of A2. Flow cytometry demonstrated increased circulating and aortic C-C chemokine receptor 2 (CCR2) monocytes during A2 infusion.
T here is no currently available drug treatment that limits abdominal aortic aneurysm (AAA) expansion. 1 The pathogenesis of AAA is multifactorial, however a chronic aortic inflammatory response is considered central to the pathogenesis. 2 Recently, a significant role of innate immune cells, particularly monocyte/macrophages, in AAA pathogenesis has been suggested. 3 Activated macrophages are believed to be a primary source of proteases responsible for aortic matrix degradation. 2 Upregulation of aortic proteolytic activity is believed to be critical in the degeneration of medial architecture associated with end-stage human AAA. 4 Chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemotactic protein 1, is a potent stimulant of monocyte recruitment through its cognate membrane receptor C-C chemokine receptor 2 (CCR2). 5 The critical role of monocyte CCR2 in the development of vascular inflammation has been consistently demonstrated in animal studies using rodents genetically deficient in CCR2, or in which CCR2 activation has been neutralized. [6] [7] [8] [9] Recent reports have highlighted an important role of CCR2 in the development of experimental aortic aneurysm. [10] [11] [12] [13] Human AAA has also been associated with polymorphism in the CCR2 gene. 14 The mechanistic target of rapamycin (mTOR) is a key regulator of mRNA translation, cell cycle progression, and cell growth. 15 Rapamycin (sirolimus) and rapamycin analogs represent a class of mTOR inhibitors with both immunosuppressive and antiproliferative properties, 16 with the rapalog everolimus originally developed for clinical use to improve outcome of organ transplantation. 17, 18 Preclinical studies have since demonstrated that everolimus inhibits migration and accumulation of monocytes/macrophages in models of vascular disease 19 and implicate mTOR signaling in the activation of these cells. 20, 21 The role of mTOR signaling in the pathogenesis of human AAA has received little attention, despite the findings that genetic mutations in upstream negative regulators of mTOR are associated with the development of thoracoabdominal aneurysm in experimental models and humans. 22 Rapamycin has been shown to inhibit AAA formation in a rat model associated with decreased levels of aortic metalloproteinase 9, 23 however, this study did not examine the effect of mTOR signaling on monocyte CCR2, which may be of particular importance in AAA pathogenesis. [10] [11] [12] [13] The present study was designed to evaluate the effect of systemically administered everolimus on monocyte CCR2 profile and AAA development in the A2-infused apolipoprotein E-deficient (ApoE -/-) mouse model.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

A2 Infusion Upregulated Circulating and Aortic CCR2 + Monocytes, Which Were Positively Correlated With Aortic Dilatation in ApoE -/-Mice
In a preliminary study, 20 male ApoE -/mice aged 15 weeks were infused with A2 (n=10) or saline (n=10) for 14 days. Two A2-infused mice died from suprarenal aortic (SRA) rupture and were excluded from the study. Blood and wholeaorta preparations were incubated with antibodies specific for CD11b, Gr1, and CCR2 and analyzed by flow cytometry. Mature monocytes expressing CCR2 were delineated by high forward scatter, low side scatter, the presence of CD11b, and the absence of Gr1, and were demonstrated at significantly higher numbers in both blood and aortas of A2-infused mice compared with saline controls ( Figure IA and IB in the onlineonly Data Supplement). Total number of aortic CCR2 monocytes correlated positively with increasing SRA diameter (Spearman r=0.857, P=0.011; Figure IC in the online-only Data Supplement).
Inhibition of A2-Induced Aortic Dilatation and SRA Aneurysm by Everolimus
Twenty-two male ApoE -/mice aged 15 weeks were subcutaneously infused with A2 over 28 days. Twelve mice received everolimus and 10 vehicle control. Two mice from the everolimus group and 1 from the control group died from complications unrelated to aneurysm formation and were not included in the study. Subsequently, analyses included 10 mice receiving everolimus and 9 controls. The effect of everolimus on SRA dilatation was monitored with ultrasound over the 28-day A2 infusion period. Median (interquartile range) maximum SRA diameter was comparable between control and everolimus mice at baseline and after 7 days of A2 infusion. By 21 days, median maximum SRA diameters were significantly different, measuring 1.50 (1.43-1.50 mm) and 1.20 (1.10-1.30 mm) in vehicle control and mice receiving everolimus, respectively (P<0.001). The difference remained significant at day 28 (P<0.001; Figure 1A ). The effect of everolimus in limiting A2-induced SRA dilatation was confirmed by morphometric analysis of aortas harvested at day 28 (P=0.026; Figure 1B and Figure II in the onlineonly Data Supplement). A trend toward reduced maximum diameters in the aortic arch, thoracic, and infrarenal aorta was also observed, however a significant difference compared with vehicle control animals could not be demonstrated ( Figure 1B) . Overall, the mean total maximum aortic diameter (±SD) was significantly lower in mice receiving everolimus compared with those administered vehicle control (1.09±0.05 and 1.36±0.12 mm, respectively; P=0.042).
Everolimus Reduced Aortic Concentration of CCR2 but Not CCL2
CCR2 and CCL2 protein were compared between mice receiving everolimus plus A2 and vehicle control plus A2 in aortas harvested at 28 days by Western blot (relative density units/mg protein). Median and interquartile range of aortic CCR2 was significantly lower in mice receiving everolimus compared with vehicle controls (1.31, 1.01-1.59 versus 1.97, 1.70-2.07; P=0.009; Figure III Immunofluorescence staining of SRA from control mice with anti-monocyte and macrophage antibody demonstrated Figure 1 . The effect of everolimus on angiotensin II (A2)-induced aortic aneurysm formation in apolipoprotein E-deficient (ApoE -/-) mice. A, Suprarenal aortic (SRA) diameter measured by ultrasound at baseline, then 14, 21, and 28 days after commencing A2 infusion in mice receiving everolimus (n=10) and vehicle control (n=9). B, Regional diameters determined by morphometric analysis at sacrifice (day 28). IRA indicates infrarenal aorta; SRA, suprarenal aorta; and TA, thoracic aorta. Data presented as median (dotted line) and interquartile range (whiskers) maximum diameter (mm).
transmural infiltration of monocytes/macrophages ( Figure III in the online-only Data Supplement). Sequential staining for CCR2 colocalized with that of anti-monocyte and macrophage antibody, suggesting aortic infiltration of CCR2-expressing monocytes. Qualitatively, the presence of CCR2 monocytes within the SRA of mice receiving everolimus appeared reduced ( Figure IV in the online-only Data Supplement).
Reduced Circulating CCR2 Monocytes in Mice Receiving Everolimus
Twelve male ApoE -/mice aged 15 weeks receiving vehicle (n=6) or everolimus (n=6) were infused with A2 over 14 days. One vehicle control mouse died from SRA rupture, so blood from this animal was excluded from the study. Flow cytometry was performed on blood samples before (baseline) and 24, 48, 96, 216, and 336 hours after commencing A2 infusion. Mature inflammatory monocytes were delineated by high forward scatter, low side scatter, the presence of Ly6B.2, the absence of Ly6G, and high expression of CCR2 ( Figure 2 ). The number of circulating CCR2 monocytes increased after 48 hours A2 infusion in both groups of mice. The number of these monocytes in vehicle control mice rose progressively over the next 12 days in response to A2 (P<0.001, analysis of variance; Figure 2 ). A similar but less significant trend was observed in the circulation of mice receiving everolimus (P=0.023). The total number of circulating monocytes expressing CCR2 was approximately 2-fold lower in mice receiving everolimus compared with vehicle controls after 4 days of A2 infusion (P=0.005; Figure 2 ). The number of CCR2 monocytes within the circulation of mice receiving everolimus mirrored baseline from 96 to 336 hours, remaining 3-fold lower than the total number of peripheral CCR2 monocytes in vehicle control mice at termination (day 14; Figure 2 ).
In Vivo Regulation of A2-Stimulated Development of Bone Marrow CCR2 Monocytes by Everolimus
Two groups of 12 male ApoE -/mice aged 15 weeks receiving vehicle (n=6) or everolimus (n=6) were infused with A2 over 48 and 168 hours, respectively. Bone marrow from mice receiving everolimus was compared with that of vehicle controls by flow cytometry at each time point. Premature inflammatory monocytes were delineated by high forward scatter, low side scatter, the absence of B220, and the presence of the monocytelineage marker CD115, inflammatory marker Ly6C, and CCR2 ( Figure 3 ). Median expression of CD115 within bone marrow decreased over time in both cohorts ( Figure 3A) ; however, it was significantly lower in mice receiving everolimus at both 48 and 168 hours (P=0.002 and 0.024, respectively; Figure 3A ). In line with this, median absolute number of CD115 + Ly6C + CCR2 hi cells present in the bone marrow of mice receiving everolimus for 48 hours was reduced 1.5-fold (P=0.015; Figure 3B ).
Dose-Dependent Stimulation of IFNγ Production and CCR2 Expression in Bone Marrow Monocytes by A2 In Vitro
Monocytes purified from male ApoE -/mouse bone marrow were cultured, otherwise unstimulated, in the presence of increasing concentrations of A2 for 36 hours. Supernatant concentrations of interleukin (IL)-6, CCL2, interferon (IFN)-γ, IL-10, and IL-12p70 were determined by cytometric bead array. Levels of IL-10 and IL-12p70 varied markedly between replicate cultures and were not consistently affected by A2 (Table) . The production of IL-6 and CCL2 tended to increase in response to increasing A2 concentrations, however, a statistically significant dose-dependent relationship could not be demonstrated (Table) . Supernatant concentration of IFNγ increased in response to A2 in a dose-dependent manner (P=0.036, Kruskal-Wallis test; Table) . A2 incubation also stimulated an increase in the number of CCR2 monocytes after 36 hours in a dose-dependent manner (P=0.002; Figure 4A ).
Inhibition of A2-and IFNγ-Stimulated CD115 Expression, and IFNγ-Stimulated CCR2 Expression in ApoE -/-Mouse Bone Marrow Monocytes by Everolimus In Vitro
Monocytes purified from ApoE -/mouse bone marrow were stimulated with either A2 or IFNγ, and cultured in the presence or absence of everolimus. Flow cytometry was used to assess the effect of everolimus on A2-and IFNγ-induced CD115 and CCR2 expression after 36 hours. Median (interquartile range) mean fluorescence intensity for CD115 in bone marrow monocytes (BMM) cultured in the presence of A2 or IFNγ were 59.79 (58.55-62.08) and 42.66 (35.68-44.50), respectively ( Figure  4B ). Both A2 and IFNγ-stimulated CD115 expression were significantly reduced in the presence of everolimus to median mean fluorescence intensities of 33.83 (31.44-34.87; P=0.008) and 32.61 (31.65-33.39; P=0.010), respectively ( Figure 4B ). CCR2 expression in cells stimulated by A2 was reduced in the presence of everolimus, however the difference was not statistically significant (38.29, 45.34-46 .97 versus 47.06, 42.67-58.78; P=0.150; Figure 4C ). In contrast, IFNγ-induced CCR2 expression was significantly lower in the presence of everolimus, with median CCR2 mean fluorescence intensity reduced from 72.90 (69.93-75.27) to 58.62 (56.71-62.92; P=0.008; Figure 4C ).
Everolimus Attenuates M1 Polarization in ApoE -/-BMM-Derived Macrophage In Vitro
Macrophages differentiated from purified ApoE -/mouse BMM were incubated with IFNγ and lipopolysaccharide (LPS) to promote M1 phenotype in the presence and absence of everolimus over 48 hours. Flow cytometry was used to assess the effect of everolimus on expression of surface markers CD206, CD11b, and F4/80, as indicators of polarity. Macrophages cultured in the presence of IFNγ/LPS exhibited markedly reduced expression of CD206 compared with unstimulated cells ( Figure  5A ) in a population comprising primarily CD11b + F4/80 lo macrophages ( Figure 5B) , with a mean F4/80 lo to F4/80 hi ratio of 10.49±5.51. The reduction in CD206 expression induced by IFNγ/LPS was counteracted in the presence of everolimus resulting in there being more cells expressing CD206, similar to that seen in unstimulated macrophages ( Figure 5A ). This observation coincided with an increase in the percentage of F4/80 hi macrophages present from 13.00±9.54 to 33.20±1.22 (P=0.029), and a reduction in the percentage of F4/80 lo macrophages from 65.08±8.27 to 50.15±8.83 (P=0.057; Figure 5B ), lowering the mean F4/80 lo to F4/80 hi ratio in the presence of everolimus to 1.69±0.36 (P=0.030). The concentration of nitrate in supernatant from macrophage cultures was taken as a measure of total cellular nitric oxide production. Median (interquartile range) nitrate concentration in supernatant from macrophages exposed to IFNγ/ LPS was 27.40 µmol/L (25.44-30.41 µmol/L) compared with 17.72 µmol/L (15. .94 µmol/L) in unstimulated macrophages (P=0.002; Figure 5C ). Nitric oxide production was reduced nearly 1.5-fold in IFNγ/LPS-stimulated macrophages cultured in the presence of everolimus, with a median nitrate/ nitrite concentration of 20.08 µmol/L (17.57-23.75 µmol/L; P=0.009; Figure 5C ), reflecting that of unstimulated control cells (P=0.240).
Table. Concentrations of Proinflammatory Cytokines Within Supernatants of ApoE -/-Bone Marrow-Derived Monocytes Cultured in the Presence of Increasing Concentration of A2 for 36 Hours
Discussion
The main new finding of this study is that everolimus administered by subcutaneous infusion inhibits A2-induced aortic dilatation in a mouse model of AAA by means of regulating bone marrow development of Ly6C + CCR2 + (inflammatory) monocytes. In vitro and animal studies have demonstrated that everolimus inhibits accumulation of monocyte in atheroma and promotes plaque stability. 19, 24 The mechanisms involved in AAA and atherosclerosis are believed to be distinct. 25 To our knowledge, this is the first study to assess the effect of everolimus in an AAA model.
An important finding here is that CCR2 monocytes appear to play a key role in A2-induced AAA formation. Two types of blood monocytes have been characterized in mice based on their pattern of expression of CCR2. 26 Monocytes exhibiting a CCR2phenotype migrate to uninjured tissues rapidly after release from bone marrow and differentiate into resident macrophages and dendritic cells. In contrast, a distinct CCR2 + monocyte subset migrates into local sites of injury and contributes to the development of inflammation. 27 In the current study, we observed that the presence of CCR2 monocytes was elevated in both the blood and aortic tissue of A2-infused ApoE -/mice compared with saline-infused controls, and that the degree of aortic dilatation in response to A2 correlated positively with the number of CCR2 monocytes present within aortic tissue. These findings are in line with reduced aortic aneurysm formation in CCR2-null mice, [10] [11] [12] [13] and further highlight the likely role of these cells in promoting aneurysm formation and growth.
Infiltration of monocytes into the inflamed vascular wall is facilitated by in situ production of chemokines. CCL2, produced by all vascular cells under inflammatory conditions, [28] [29] [30] is the cognate ligand for CCR2 and regulates inflammatory monocyte recruitment to sites of infection or injury. 5 Current experimental evidence implicating the mTOR pathway in the modulation of vascular CCL2 is conflicting. 31, 32 Our finding that systemic administration of everolimus had little effect on aortic concentration of CCL2 in the A2 mouse model led us to conclude that a reduced presence of CCR2 monocytes within the aortic wall was more likely associated with an effect of everolimus on the circulating profile of these cells, rather than an effect on local tissue CCL2 expression. Indeed, an observed time-dependent increase in circulating CCR2 monocytes in response to A2 infusion was blocked in mice receiving concomitant infusion with everolimus.
As such, we focused our attention on the bone marrow to assess how everolimus might be acting to limit CCR2 monocyte entry into the circulation. CCR2 is important for both the egress of inflammatory monocytes from the bone marrow and for their entry into target tissues. 27 The observed reduction in the total number of premature inflammatory monocytes within the bone marrow of mice receiving everolimus compared with vehicle indicated that systemic blockade of mTOR resulted in the suppression of in situ development of these cells. This effect was seen after 48 hours, which correlates well with the reduced number of CCR2 monocytes detected within the circulation of mice receiving everolimus after 96 hours. Macrophage colony-stimulating factor plays a key role in the development of the monocytes/ macrophage phagocytotic system, and its receptor, CD115 (colony stimulating factor 1 receptor and macrophage colony-stimulating factor receptor), is an identifying marker of all cells constituting the monocytes/macrophage phagocytotic system, including progenitors, circulating monocytes, and macrophages. 33 Previous work has demonstrated that colony-stimulating factor-induced proliferation of bone marrow-derived mononuclear phagocytes in vitro is inhibited in the presence of rapamycin, 34 linking downstream mTOR activation with CD115 signaling in these cells. Our current finding that mTOR inhibition by everolimus led to a significant decrease in CD115 expression in BMM, both in vivo and in vitro, further suggests that the effect of mTOR-inhibition to suppress expansion of BMM in vivo results more from receptor (CD115) downregulation rather than blockade of downstream signaling.
It has been reported that A2 promotes macrophage colonystimulating factor-induced differentiation from hematopoietic stem cells into monocyte-lineage cells through upregulation of the macrophage colony-stimulating factor receptor. 35 As the A2-infused ApoE -/mouse model was used in the current study, we examined the action of A2 on purified ApoE -/mouse BMM in vitro and demonstrated dose-dependent stimulation of both CCR2 expression and IFNγ production in these cells. The significance of this lies in the fact that IFNγ signaling has been implicated in monocyte activation and recruitment in chronic inflammation. 36 Our findings suggest that A2-infusion promoted expansion of CCR2 monocytes within the bone marrow via IFNγ signaling. The ability of IFNγ receptor signaling to stimulate CCR2-dependent mobilization of BMM has recently been reported. 37 Importantly, Type I (α, β, δ, ε, κ, ω) and Type II (γ) IFNs have been shown to activate the mTOR pathway. 38 This fits with our in vitro observation in BMM that IFNγ-stimulated CCR2 expression was suppressed by everolimus. Thus, we suggest that, in addition to restricting the development of CCR2 monocytes within the bone marrow through the downregulation of CD115, everolimus may limit their egress from bone marrow by negative regulation of CCR2 via the inhibition of IFNγ-activated mTOR signaling.
During inflammation, Ly6C hi monocytes translocate from the bone marrow into the circulation with subsequent tissue entry giving rise to M1 (classical activation) and M2 (alternative activation) macrophages. 39 Increased production of superoxide anions, and oxygen and nitrogen radicals is characteristic of classical activation and M1 differentiation, whereas CD206 (mannose receptor) is a signature marker for alternative activation and the M2 phenotype. 40 In vitro, an M1 phenotype can be induced in macrophages by exposure to IFNγ and LPS. 43 We examined the effect of mTOR blockade on IFNγ/LPS-stimulated M1 polarization in ApoE -/mouse BMM-derived macrophages, and observed that concurrent incubation with everolimus resulted in decreased nitrogen radical production and preserved cell surface expression of CD206 and F4/80. Others have reported that transition from Ly6C hi to Ly6C lo (anti-inflammatory) macrophages is associated with an upregulation of F4/80 expression, 41 and that F4/80 Hi cells, but not F4/80 lo cells, are positive for the M2-type activation marker, CD206. 42 Taken together, our in vitro findings support an action of everolimus and mTOR blockade in limiting M1 polarization in macrophages, and, in light of a very recent report linking rupture of cerebral aneurysms with an upregulation of M1 cells and an M1/M2 imbalance within the vessel wall, 43 has important implications in terms of identifying a potential therapeutic target for AAA.
Several study limitations are highlighted. A dysregulated immune response within the aortic wall is commonly accepted, at present, as a contributing factor in the development of human AAA. Lymphocyte expression of CCR2 may be important in the activation and migratory characteristics of these cells, 44 whereas the mTOR pathway is emerging as a critical regulator of T-cell, B-cell, and antigen-presenting cell differentiation, activation, and function. 45 Whether an immunosuppressant effect of everolimus on circulating and aortic lymphocyte profile (eg, T-cell subsets) played a role in limiting A2-induced aortic dilatation was not addressed here. Second, the conclusion that a reduced circulating profile of inflammatory monocytes in the presence of everolimus resulted from decreased development of these cells within the bone marrow was extrapolated from noncontinuous observation, in that temporal comparison between blood and bone marrow samples from the same animal was negated by the terminal consequence of bone marrow harvest. Finally, our data indicating the potential for mTOR blockade to alter macrophage polarization were obtained from an in vitro model of an induced inflammatory (M1) phenotype, which demonstrated an effect of everolimus to attenuate M1 polarization. Whether everolimus may act to promote an anti-inflammatory (M2) macrophage phenotype was not addressed.
In summary, we report for the first time that the mTOR inhibitor everolimus protects against A2-induced aortic dilatation and aneurysm formation in the ApoE -/mouse model. This effect appears to be because of the limiting of development and mobilization of bone marrow CCR2 monocytes. An additional effect of everolimus-mediated mTOR inhibition to negatively regulate M1 polarization in ApoE -/mouse BMMderived macrophages in vitro is reported.
